Bioavailability Study of COQUN ORAL FORMULATION

Inclusion Criteria: * Subject Informed consent form (ICF) is signed * M \& F Aged between 35-75 years at the time of the signature of ICF * A body mass index between 20 and 29 kg/m2 * Fasting the night before enrolment, for at least 10 hours * Healthy, meaning absence of any prescribed medication for a month prior to the inclusion to the study and during the study * Willing to avoid a consumption of any food supplements except vitamin D and calcium at least 2 weeks before and during the study * Consumption of dairy and cereal products (standardized breakfast will include low lactose dairy and bread) * Willing to follow all study procedures, including attending all site visits (including sessions during which a venous line will be inserted for blood sampling), and keeping a diary for the time of multiple-dose study (to follow their compliance and palatability) Exclusion Criteria: * Intake of any prescribed medication within 2 weeks of the beginning of the study * Intake of any food supplements within 2 weeks of the beginning of the study, except vitamin D and calcium * Hypotension * Any clinically significant history of serious digestive tract, liver, kidney, cardiovascular or hematological disease, diabetes * Gastrointestinal disorders or other serious acute or chronic diseases * Known lactose/gluten intolerances/ food allergies (limitation for standardization of meals) * Inadequate veins (in the opinion of the investigator) or known contraindication to placement of a dedicated peripheral line for venous blood withdrawal * Known drug and/or alcohol abuse * Using any form of nicotine or tobacco * Mental incapacity that precludes adequate understanding or cooperation * Participation in another investigational study or blood donation within 3 months prior to or during this study